Last updated: August 22, 2026
Ziprasidone mesylate is the injectable salt of ziprasidone used for short-term intramuscular treatment of acute agitation in adults with schizophrenia. Its commercial value is driven less by API novelty than by formulation execution: rapid reconstitution, reliable dose delivery, low injection volume, chemical stability, and hospital workflow. The reference formulation uses sulfobutyl ether beta-cyclodextrin sodium, a solubilizing excipient that creates the main opportunity for differentiated generic, lifecycle-management, and specialty injectable products [1].
The strongest commercial strategies are ready-to-use presentations, improved reconstitution systems, lower excipient burden, container-closure improvements, and hospital-oriented supply reliability. Oral ziprasidone should be treated as a separate product because it uses ziprasidone hydrochloride monohydrate and has a different absorption and excipient profile.
What is ziprasidone mesylate and how is it used?
Ziprasidone mesylate is a mesylate salt of the atypical antipsychotic ziprasidone. The approved injectable product is supplied as a sterile lyophilized powder for intramuscular reconstitution.
| Attribute |
Reference injectable product |
| Active ingredient |
Ziprasidone mesylate |
| Strength |
20 mg/mL after reconstitution |
| Route |
Intramuscular |
| Indication |
Acute agitation in adults with schizophrenia |
| Presentation |
Single-dose vial containing sterile powder |
| Reconstitution |
Sterile water for injection |
| Key solubilizer |
Sulfobutyl ether beta-cyclodextrin sodium |
| Administration limit |
Maximum recommended dose of 40 mg/day |
| Typical dosing interval |
10 mg every 2 hours or 20 mg every 4 hours |
| Oral-to-injectable substitution |
Not established as a direct milligram-for-milligram substitution |
The injectable formulation is intended for short-term use when oral therapy is impractical. The label limits treatment to three consecutive days and requires transition to oral ziprasidone when clinically appropriate [1].
What excipients are used in ziprasidone mesylate injection?
The principal formulation excipient is sulfobutyl ether beta-cyclodextrin sodium, commonly abbreviated SBECD. It is a modified cyclodextrin used to improve aqueous solubility by forming inclusion complexes with poorly water-soluble drug molecules.
The reference injectable formulation relies on a relatively simple excipient system:
- Ziprasidone mesylate as the active pharmaceutical ingredient.
- SBECD as the solubilizer.
- Sterile water for injection as the reconstitution medium.
The absence of a conventional preservative is commercially relevant. The product is supplied as a single-dose vial and is not designed for multidose storage after reconstitution [1].
Why is SBECD strategically important?
SBECD affects several development variables:
- Drug solubility at the target concentration.
- Reconstitution time.
- Solution clarity.
- pH and chemical stability.
- Osmolality and injection tolerability.
- Lyophilization cycle design.
- Vial fill volume and cake structure.
- Regulatory comparability with the reference product.
SBECD also creates a potential barrier to low-cost formulation redesign. Replacing it with a different solubilizer may change the drug’s solution chemistry, safety package, reconstitution behavior, and bioequivalence strategy.
What formulation problems create commercial opportunities?
The reference product is functional, but hospital use creates several areas for improvement.
Reconstitution time
A powder requiring reconstitution introduces preparation steps in emergency and inpatient settings. A product that reduces shaking, eliminates visible particles, or shortens dissolution time could have procurement value even without changing the active ingredient.
A ready-to-use liquid would offer the largest workflow benefit, but it would also create the greatest development burden. The developer would need to address long-term chemical stability, precipitation risk, container compatibility, sterility assurance, and injection-site tolerability.
Product waste
Single-dose injectable antipsychotics can generate waste when the prescribed dose is lower than the vial content or when a prepared dose is not administered. Smaller vial sizes, prefilled syringes, or dose-specific presentations could improve utilization.
The tradeoff is manufacturing complexity. Multiple strengths can increase packaging, inventory, validation, and supply-chain costs.
Hospital preparation risk
A reconstitution system with an integrated diluent, dual-chamber device, or prefilled syringe could reduce manipulation. Such products may be attractive in emergency departments, psychiatric hospitals, and medical centers with high injectable antipsychotic use.
The device can create a separate intellectual-property position even when the drug formulation itself is difficult to protect.
Injection-site tolerability
A reformulated product could target lower injection volume, reduced osmolality, optimized pH, or lower excipient concentration. Any such change would require evidence that the formulation does not increase pain, induration, tissue injury, or local adverse reactions.
Stability and supply reliability
A formulation with improved moisture protection, longer shelf life, or less sensitivity to transport conditions could appeal to hospital purchasers. Packaging changes may provide a practical lifecycle strategy when broad composition claims are difficult to obtain.
What excipient alternatives could replace or complement SBECD?
Potential alternatives include other cyclodextrins, cosolvents, surfactants, hydrotropes, and pH-modifying systems. Each option has different regulatory and technical implications.
| Excipient approach |
Potential benefit |
Principal risk |
| Alternative cyclodextrin |
May preserve complexation-based solubility |
Different safety, renal, and regulatory profile |
| Cosolvent system |
May reduce cyclodextrin quantity |
Injection-site irritation and precipitation |
| Surfactant |
Can improve wetting and solubilization |
Hemolysis, local tolerability, and degradation risk |
| pH optimization |
May increase apparent solubility |
Precipitation after dilution or injection |
| Mixed solubilizer system |
May lower total amount of any single excipient |
More complex control strategy |
| Nanoparticle or amorphous system |
Could support concentrated liquid delivery |
Higher CMC and clinical comparability burden |
| Lyophilized co-formulation |
May improve cake and reconstitution properties |
Cycle development and moisture sensitivity |
The most realistic near-term approach is optimization around SBECD rather than immediate replacement. A developer could evaluate SBECD concentration, drug-to-excipient ratio, buffer selection, cake structure, vial headspace, and reconstitution instructions while preserving the reference product’s core chemistry.
What formulations are protected by patents?
The commercial protection of ziprasidone mesylate injection is likely to depend more on formulation, device, manufacturing, and packaging claims than on the basic ziprasidone molecule. The original ziprasidone compound and oral product patents have long-standing expiration history, and generic entry has occurred in the United States for oral and injectable presentations.
Relevant claim categories include:
- Sterile injectable compositions containing ziprasidone mesylate and SBECD.
- Specific drug-to-cyclodextrin ratios.
- Lyophilized cakes with defined residual moisture.
- Reconstitution methods and solution concentrations.
- Prefilled syringes or dual-chamber delivery systems.
- Container-closure systems that limit moisture ingress.
- Manufacturing processes for sterile filling and lyophilization.
- Methods of treating acute agitation using injectable ziprasidone.
A formulation patent must be evaluated for claim scope, written-description support, enablement, obviousness, and terminal disclaimers. Broad claims covering ziprasidone plus a known injectable solubilizer face a higher obviousness risk than narrowly defined claims tied to a specific concentration, stability profile, process parameter, or device configuration.
What is the FDA regulatory status of ziprasidone mesylate injection?
The FDA-approved reference product is Geodon for injection, marketed by Pfizer. The product is regulated as a small-molecule injectable drug rather than a biologic. Generic competitors use the abbreviated new drug application pathway and generally must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements [1, 2].
Key regulatory considerations include:
- Same active ingredient and route of administration.
- Equivalent dosage form and strength.
- Sterility and particulate controls.
- Container-closure integrity.
- Reconstitution performance.
- Stability through the labeled shelf life.
- Comparative quality attributes.
- Injectable-product facility compliance.
For a conventional generic powder-for-reconstitution product, clinical efficacy trials are generally not the principal approval requirement. A materially different delivery system, new excipient, ready-to-use liquid, or sustained-release product can create a larger regulatory package.
What is the Orange Book status and generic entry risk?
FDA Orange Book listings determine whether listed patents may affect ANDA approval and Paragraph IV certification. The Orange Book should be reviewed by product presentation because oral ziprasidone hydrochloride and injectable ziprasidone mesylate are separate products with different formulation and patent histories [2].
Generic entry risks fall into four categories:
- Listed patent risk, including Paragraph IV litigation.
- Injectable manufacturing risk, particularly aseptic processing and lyophilization.
- Supply risk caused by limited qualified SBECD or sterile manufacturing capacity.
- Commercial risk from low hospital prices and established generic competition.
Paragraph IV exposure is usually lower where no active Orange Book patent blocks approval. It can remain relevant for later-added formulation or device patents, especially when those patents are listed against an approved product and have claims that meet FDA listing requirements.
The available FDA approval and labeling sources do not establish a current, comprehensive litigation or settlement position for every ziprasidone mesylate manufacturer. Patent counsel should verify active Orange Book listings, Federal Court filings, ANDA notices, and settlement terms before relying on a launch date.
Which companies are positioned in the ziprasidone market?
Pfizer owns the reference Geodon franchise. Generic competition has been introduced by manufacturers that have obtained FDA approval for ziprasidone capsules and injectable products. Competitive differentiation is likely to depend on supply continuity, hospital contracting, vial configuration, and customer service rather than on brand recognition.
The relevant competitor groups are:
- Pfizer and the reference product.
- Generic injectable manufacturers with approved ANDAs.
- Contract development and manufacturing organizations with sterile lyophilization capacity.
- Specialty pharmaceutical companies developing prefilled or integrated-delivery presentations.
- Hospital-focused suppliers offering bundled psychiatric emergency products.
For a new entrant, the most attractive commercial position is usually a differentiated presentation with a clear operational benefit, not another conventional powder vial at a lower price.
How strong is the patent estate for ziprasidone mesylate?
The basic molecule has limited remaining exclusivity value because ziprasidone has been commercially available for many years. The strongest protectable positions are likely to be narrow and implementation-specific.
| Asset type |
Likely protection strength |
Commercial relevance |
| Basic ziprasidone composition |
Low for new entry |
Historical importance |
| Mesylate salt alone |
Low to moderate |
Depends on claim scope and prior art |
| SBECD injectable composition |
Moderate if narrowly claimed |
Core formulation protection |
| Specific lyophilization process |
Moderate |
Manufacturing differentiation |
| Ready-to-use liquid |
Moderate to high if stable and nonobvious |
Strong workflow value |
| Prefilled or dual-chamber device |
Moderate to high |
Product differentiation |
| Method-of-use claim |
Low to moderate |
Vulnerable if treatment use is established |
| Packaging and moisture-control claim |
Moderate |
Supports shelf-life strategy |
The patent estate should be assessed as a layered portfolio. Composition claims alone are unlikely to provide a durable new-product barrier. A stronger portfolio would combine formulation, process, device, packaging, and method-of-use claims across the United States, Europe, Japan, and other major markets.
What manufacturing and IP barriers affect market entry?
The main manufacturing barriers are sterile processing, control of endotoxin and particulate levels, lyophilization scale-up, vial filling, and reproducible reconstitution. SBECD handling and supplier qualification can also affect cost and continuity.
A commercial developer should protect:
- Supplier specifications for SBECD.
- Particle-size and moisture controls.
- API salt form and polymorphic state.
- Lyophilization cycle parameters.
- Reconstitution time and visual clarity.
- Vial and stopper compatibility.
- Stability-indicating analytical methods.
- Device interfaces for integrated delivery.
Trade secrets may be more valuable than patents for cycle parameters, formulation screening data, and scale-up controls. Patents remain important for visible product attributes that competitors can reverse-engineer.
How does injectable ziprasidone compare with oral ziprasidone?
| Attribute |
Injectable ziprasidone mesylate |
Oral ziprasidone hydrochloride |
| Primary use |
Acute agitation |
Maintenance and acute psychiatric treatment when oral therapy is feasible |
| Dosage form |
Powder for IM reconstitution |
Capsule |
| Key formulation issue |
Solubility and sterile delivery |
Food-dependent absorption |
| Major excipient strategy |
Cyclodextrin solubilization |
Capsule fill, disintegration, and solid-state control |
| Commercial opportunity |
Ready-to-use delivery and hospital workflow |
Generic cost, adherence, and formulation convenience |
| Bioequivalence focus |
Injectable quality and reconstitution |
Oral exposure under fed conditions |
Oral ziprasidone must be administered with food for adequate absorption. That requirement creates a separate opportunity for oral formulation development, but it does not directly solve the injectable product’s formulation challenges [3].
What are the highest-value commercial opportunities?
The best opportunities rank as follows:
- Ready-to-use liquid injection with a commercially meaningful shelf life.
- Prefilled syringe or dual-chamber system that eliminates manual reconstitution.
- Smaller-dose or dose-specific vials that reduce waste.
- SBECD-optimized formulation with faster reconstitution and lower injection volume.
- Improved moisture-barrier packaging and extended shelf life.
- Hospital supply agreements tied to psychiatric emergency departments.
- Regional licensing of sterile injectable manufacturing and distribution rights.
- Combination supply contracts covering ziprasidone and other acute agitation injectables.
Licensing value will depend on whether the asset is a conventional generic, a differentiated formulation, or a delivery platform that can be reused with other poorly soluble injectable drugs. A platform with validated SBECD formulation know-how, sterile lyophilization capability, and an integrated delivery device may have greater strategic value than a single-product license.
Key Takeaways
- Ziprasidone mesylate injection is a sterile, lyophilized intramuscular product centered on SBECD solubilization.
- The leading excipient opportunity is optimization of the existing cyclodextrin system, not an unvalidated excipient replacement.
- Ready-to-use and integrated-delivery formats offer the clearest commercial differentiation.
- The basic ziprasidone molecule provides limited new-entry protection; formulation, device, process, and packaging claims are more relevant.
- Generic entry risk is driven by FDA approval status, Orange Book listings, sterile manufacturing capacity, and hospital pricing.
- Oral ziprasidone hydrochloride is a separate formulation and regulatory opportunity because of its food-dependent absorption.
- Hospital workflow, waste reduction, reconstitution time, and supply continuity are the main purchasing drivers.
FAQs
Can SBECD be removed from ziprasidone mesylate injection?
Yes, but removal would require a new solubility and stability strategy. A replacement system would need to demonstrate acceptable safety, clarity, reconstitution, injection tolerability, and product stability.
Is a prefilled ziprasidone injection commercially feasible?
It is technically feasible, but the liquid formulation must remain stable and free of precipitation throughout storage. The device would also require container-closure, sterility, extractables, and usability validation.
Does ziprasidone mesylate injection have biosimilar risk?
No. Ziprasidone mesylate is a chemically synthesized small molecule. Competitive risk comes from generic ANDAs and differentiated injectable formulations, not biosimilars.
What patent claims are most defensible for a new ziprasidone injectable?
Narrow claims directed to a defined formulation ratio, stability profile, lyophilization process, reconstitution performance, or integrated delivery device are generally more defensible than broad claims covering ziprasidone and a conventional solubilizer.
What geographic markets are most attractive for a differentiated product?
The United States offers the strongest hospital and specialty-injectable market opportunity but has demanding regulatory and manufacturing requirements. Europe and Japan may offer additional value for ready-to-use presentations, while emerging markets may prioritize low cost, shelf life, and reliable supply.
References
-
U.S. Food and Drug Administration. (2024). Geodon (ziprasidone mesylate) for injection prescribing information. Pfizer Laboratories. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024). Ziprasidone hydrochloride capsule prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (2014). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/
-
European Medicines Agency. (2024). European public assessment information for ziprasidone-containing medicinal products. https://www.ema.europa.eu/
